A Phase 1 interventional study of LY3002813-IV and LY3002813-SC in Alzheimer Disease, sponsored by Eli Lilly and Company. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.
Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 12th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 1, and was the 1st registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:
Banner Health · Sites in Colombia
Ages 25–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Japan, Puerto Rico
Ages 55+
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Eli Lilly and Company · Sites in China
Ages 55–80
Paul S. Aisen · Sites in United States
Ages 50–80
By country, each count listing its studies:
donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2013; this study’s year is marked. 1 started in 2013.
This study's enrollment of 63 is close to the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 240 across the 15 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 4 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 55th largest by enrollment of the 95 interventional ones that give a count, is one of 7 that started in 2013, is one of 34 in phase 1, and was the 41st registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
1 of the studies testing donanemab in Alzheimer Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026866Phase 3Eli Lilly and CompanyA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing donanemab in Alzheimer Disease, from their registry updates:
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813. Study participants will be healthy or will have mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.
There will be seven groups of study participants. Five groups will receive a single dose of LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo given as an injection into a vein. Approximately 12 weeks will pass between the single dose and the first multiple dose. One group of participants will receive a single dose of LY3002813 given as an injection under the skin. One group of participants will receive a single dose of LY3002813 given as an injection into a vein.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy Participants:
Participants with Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or AD:
Exclusion Criteria:
-Healthy Participants: Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, immunological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
Participants with Mild Cognitive Impairment Due to AD or AD:
All Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
Biological: LY3002813-IV
0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
Biological: LY3002813-IV
1 mg/kg single dose LY3002813 given once by IV infusion.
Biological: LY3002813-IV
1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
Biological: LY3002813-IV
3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
Biological: LY3002813-IV
10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
Biological: LY3002813-IV
Placebo given once, then every 4 weeks for up to 16 weeks IV
Drug: Placebo-IV
Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
Biological: LY3002813-SC
Up to 3mg/kg LY3002813 given once intravenously (IV)
Biological: LY3002813-IV
Administered IV
Administered SC
Administered IV
Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Data presented are the number of participants who experienced SAEs which were considered to be related to study treatment by the investigator while on treatment and during the follow-up. Summaries of SAEs and other non-serious adverse events (AEs), regardless of causality, are located in the Reported Adverse Events module.
Time frame: Day 1 up to Day 253
Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813
Maximum Concentration (Cmax) of LY3002813 after the first dose was evaluated.
Time frame: Pre-dose, end of infusion for IV or 1h post injection for SC, 3, 24, 72, 96(SC), 120(SC), 144(SC), 168, 336, 504, 672, 1008, 1344, 1680 and 2016 hours (h) post-dose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY3002813
Area Under the Concentration Versus Time Curve From Time Zero to Infinity \[AUC(0-∞)\] of LY3002813 after the first dose was evaluated.
Time frame: Pre-dose, end of infusion for IV or 1h post injection for SC, 3, 24, 72, 96(SC), 120(SC), 144(SC), 168, 336, 504, 672, 1008, 1344, 1680 and 2016h post-dose
| Milestone | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC |
|---|---|---|---|---|---|---|---|---|
| Started | 12 | 4 | 7 | 6 | 9 | 11 | 6 | 8 |
| Received at least 1 dose of study drug | 12 | 4 | 7 | 6 | 9 | 11 | 6 | 8 |
| Completed | 11 | 4 | 7 | 6 | 8 | 9 | 5 | 8 |
| Not completed | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Data presented are the number of participants who experienced SAEs which were considered to be related to study treatment by the investigator while on treatment and during the follow-up. Summaries of SAEs and other non-serious adverse events (AEs), regardless of causality, are located in the Reported Adverse Events module.
| Participants | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
Maximum Concentration (Cmax) of LY3002813 after the first dose was evaluated.
| microgram per milliliter (μg/mL) | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813 | 2.90 ± 35 | 5.99 ± 77 | 31.5 ± 29 | 21.7 ± 21 | 71.6 ± 24 | 218 ± 16 | 12.0 ± 34 |
Area Under the Concentration Versus Time Curve From Time Zero to Infinity \[AUC(0-∞)\] of LY3002813 after the first dose was evaluated.
| microgram*day per milliliter (μg*day/mL) | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY3002813 | 7.94 ± 32 | 26.3 ± 33 | 91.6 ± 17 | 79.9 ± 26 | 263 ± 19 | 1140 ± 39 | 157 ± 41 |
Collected over Day 1 up to Day 253. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo IV | — | 1/12 (8.3%) | 8/12 (66.7%) |
| 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | — | 0/4 (0%) | 3/4 (75%) |
| 0.3 mg/kg LY3002813 IV | — | 2/7 (28.6%) | 4/7 (57.1%) |
| 1 mg/kg LY3002813 IV: Healthy Participants | — | 0/6 (0%) | 3/6 (50%) |
| 1 mg/kg LY3002813 IV | — | 1/9 (11.1%) | 6/9 (66.7%) |
| 3 mg/kg LY3002813 IV | — | 0/11 (0%) | 7/11 (63.6%) |
| 10 mg/kg LY3002813 IV | — | 0/6 (0%) | 2/6 (33.3%) |
| 3 mg/kg LY3002813 SC | — | 0/8 (0%) | 4/8 (50%) |
| Event | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC |
|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/12 | 0/4 | 1/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| Hip fractureInjury, poisoning and procedural complications | 0/12 | 0/4 | 1/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 0/12 | 0/4 | 0/7 | 0/6 | 1/9 | 0/11 | 0/6 | 0/8 |
| Non-cardiac chest painGeneral disorders | 1/12 | 0/4 | 0/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| Event | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC |
|---|---|---|---|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 0/12 | 0/4 | 1/7 | 0/6 | 2/9 | 3/11 | 0/6 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/4 | 1/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| Chest discomfortGeneral disorders | 0/12 | 1/4 | 0/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 1/4 | 0/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| ParkinsonismNervous system disorders | 0/12 | 1/4 | 0/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| ApathyPsychiatric disorders | 0/12 | 1/4 | 0/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| Urinary retentionRenal and urinary disorders | 0/12 | 1/4 | 0/7 | 0/6 | 0/9 | 0/11 | 0/6 | 0/8 |
| FallInjury, poisoning and procedural complications | 0/12 | 0/4 | 0/7 | 0/6 | 1/9 | 2/11 | 0/6 | 1/8 |
| NauseaGastrointestinal disorders | 0/12 | 0/4 | 0/7 | 1/6 | 0/9 | 1/11 | 0/6 | 0/8 |
| VomitingGastrointestinal disorders | 0/12 | 0/4 | 0/7 | 1/6 | 0/9 | 0/11 | 0/6 | 0/8 |
All enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 76.8 ± 4.9 | 71.3 ± 11.6 | 75.0 ± 8.4 | 25.8 ± 3.3 | 74.7 ± 9.3 | 73.0 ± 8.8 | 72.3 ± 10.7 | 74.5 ± 9.5 | 69.7 ± 16.4 |
| Sex: Female, Male(Participants) | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 3 | 4 | 0 | 4 | 8 | 2 | 5 | 33 |
| Male | 5 | 1 | 3 | 6 | 5 | 3 | 4 | 3 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 4 |
| Not Hispanic or Latino | 12 | 4 | 7 | 4 | 8 | 11 | 5 | 8 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 5 | 2 | 3 | 0 | 3 | 4 | 2 | 2 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 3 |
| White | 6 | 2 | 3 | 5 | 6 | 6 | 4 | 6 | 38 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo IV | 0.1 mg/kg / 0.3 mg/kg LY3002813 IV | 0.3 mg/kg LY3002813 IV | 1 mg/kg LY3002813 IV: Healthy Participants | 1 mg/kg LY3002813 IV | 3 mg/kg LY3002813 IV | 10 mg/kg LY3002813 IV | 3 mg/kg LY3002813 SC | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 8 | 2 | 4 | 6 | 6 | 7 | 4 | 6 | 43 |
| Japan | 4 | 2 | 3 | 0 | 3 | 4 | 2 | 2 | 20 |
Ran from May 2013 to primary completion in Aug 2016, 39 months.
Results were first posted in Oct 2024, 8 years 1 month after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 39 months is above that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donanemab